Wiener medizinische Wochenschrift
-
Wien Med Wochenschr · Feb 2011
Review Comparative StudyNew anticoagulants: pharmacology and clinical studies.
The marketing of new anticoagulant drugs has led us to review the development of rivaroxaban and apixaban (oral anti-Xa drugs) and dabigatran (an oral thrombin inhibitor). The results are different in terms of efficacy and tolerance. ⋯ Though the results are favourable for these orally active drugs in the orthopaedic setting, it is clear that only cardiological applications will give a final green light for these products. The future will be fascinating in this regard.